OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
1.520
-0.050 (-3.18%)
At close: Aug 11, 2026, 4:00 PM EDT
1.600
+0.080 (5.26%)
After-hours: Aug 11, 2026, 4:22 PM EDT
Company Description
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis.
The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited
| Country | United Kingdom |
| Founded | 2007 |
| IPO Date | May 17, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Robert Dempsey |
Contact Details
Address: 14/15 Conduit St, Floor 4 London, W1S 2XJ United Kingdom | |
| Phone | 44 20 7495 2379 |
| Website | okyopharma.com |
Stock Details
| Ticker Symbol | OKYO |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 1849296 |
| CUSIP Number | 679345108 |
| ISIN Number | GG00BMFG5F62 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert J. Dempsey M.B.A. | Chief Executive Officer and Executive Director |
| Keeren Shah | Chief Financial Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
| Dr. Gary S. Jacob Ph.D. | Chief Development Officer and Director |
| Dr. Flavio Mantelli M.D., Ph.D. | Chief Medical Officer |
| Michael Paul Beck | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2026 | 20-F/A | Filing |
| Jul 28, 2026 | 6-K | Report of foreign issuer |
| Jul 27, 2026 | 6-K | Report of foreign issuer |
| Jul 23, 2026 | 6-K | Report of foreign issuer |
| Jul 23, 2026 | 6-K | Report of foreign issuer |
| Jul 22, 2026 | 6-K | Report of foreign issuer |
| Jul 22, 2026 | 6-K | Report of foreign issuer |
| Jul 22, 2026 | 6-K | Report of foreign issuer |
| Jul 21, 2026 | 6-K | Report of foreign issuer |
| Jul 21, 2026 | 6-K | Report of foreign issuer |